collection
Collections Hematología

Hematología

Reviews de todos los temas de hematología benigna y maligna

https://read.qxmd.com/read/31292909/eltrombopag-in-immune-thrombocytopenia-aplastic-anemia-and-myelodysplastic-syndrome-from-megakaryopoiesis-to-immunomodulation
#21
REVIEW
Bruno Fattizzo, Giorgia Levati, Ramona Cassin, Wilma Barcellini
Eltrombopag is an orally available thrombopoietin receptor agonist indicated for the treatment of immune thrombocytopenia (ITP). Beyond the effect on megakaryopoiesis, the drug also showed a stimulating effect on the hematopoietic stem cell with consistent clinical efficacy in aplastic anemia (AA) and myelodysplastic syndromes (MDS). Eltrombopag is highly effective in ITP and less so in AA and MDS. This observation underlines the importance of residual normal hematopoiesis, which is maximal in ITP, minimal/absent in AA, and dysregulated in MDS...
August 2019: Drugs
https://read.qxmd.com/read/32212178/multiple-myeloma-2020-update-on-diagnosis-risk-stratification-and-management
#22
REVIEW
S Vincent Rajkumar
DISEASE OVERVIEW: Multiple myeloma accounts for approximately 10% of hematologic malignancies. DIAGNOSIS: The diagnosis requires ≥10% clonal bone marrow plasma cells or a biopsy proven plasmacytoma plus evidence of one or more multiple myeloma defining events (MDE) namely CRAB (hypercalcemia, renal failure, anemia, or lytic bone lesions) features felt related to the plasma cell disorder, bone marrow clonal plasmacytosis ≥60%, serum involved/uninvolved free light chain (FLC) ratio ≥100 (provided involved FLC is ≥100 mg/L), or >1 focal lesion on magnetic resonance imaging (MRI)...
May 2020: American Journal of Hematology
https://read.qxmd.com/read/31776467/extramedullary-multiple-myeloma
#23
REVIEW
Manisha Bhutani, David M Foureau, Shebli Atrash, Peter M Voorhees, Saad Z Usmani
Extramedullary multiple myeloma (EMM) is an aggressive subentity of multiple myeloma, characterized by the ability of a subclone to thrive and grow independent of the bone marrow microenvironment, resulting in a high-risk state associated with increased proliferation, evasion of apoptosis and treatment resistance. Despite improvement in survival for most patients with multiple myeloma over recent decades, outcomes are generally poor when EMM develops. Understanding the molecular underpinnings leading to homing of plasma cells in ecosystems outside the bone marrow will be crucial for therapeutically manipulating the microenvironment and targeting key signaling pathways...
January 2020: Leukemia
https://read.qxmd.com/read/31830663/recent-update-in-the-pathogenesis-and-treatment-of-chemotherapy-and-cancer-induced-anemia
#24
REVIEW
Hikmat Abdel-Razeq, Hasan Hashem
Cancer and chemotherapy-induced anemia (CIA) is commonly encountered among patients undergoing active chemotherapy with or without radiation therapy. Its pathogenesis is complex and is often difficult to identify. Symptoms related to CIA may have a negative impact on quality of life and may influence treatment efficacy, disease progression and even survival. The recent major setback of erythropoietin-stimulating agents (ESAs) and the reluctance to transfuse cancer patients with mild and even moderate anemia, had resulted in significant under-treatment of CIA...
January 2020: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/31364186/chronic-lymphocytic-leukemia-2020-update-on-diagnosis-risk-stratification-and-treatment
#25
REVIEW
Michael Hallek
DISEASE OVERVIEW: Chronic lymphocytic leukemia (CLL) is the commonest leukemia in western countries. The disease typically occurs in elderly patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that impair apoptosis of clonal B-cells. DIAGNOSIS: The diagnosis is established by blood counts, blood smears, and immunophenotyping of circulating B-lymphocytes, which identify a clonal B-cell population carrying the CD5 antigen, as well as typical B-cell markers...
November 2019: American Journal of Hematology
https://read.qxmd.com/read/31715055/the-role-of-iron-repletion-in-adult-iron-deficiency-anemia-and-other-diseases
#26
REVIEW
Benjamin Elstrott, Lubna Khan, Sven Olson, Vikram Raghunathan, Thomas DeLoughery, Joseph J Shatzel
Iron deficiency anemia (IDA) is the most prevalent and treatable form of anemia worldwide. The clinical management of patients with IDA requires a comprehensive understanding of the many etiologies that can lead to iron deficiency including pregnancy, blood loss, renal disease, heavy menstrual bleeding, inflammatory bowel disease, bariatric surgery, or extremely rare genetic disorders. The treatment landscape for many causes of IDA is currently shifting toward more abundant use of intravenous (IV) iron due to its effectiveness and improved formulations that decrease the likelihood of adverse effects...
March 2020: European Journal of Haematology
https://read.qxmd.com/read/31591741/hairy-cell-leukemia-2020-update-on-diagnosis-risk-stratification-and-treatment
#27
REVIEW
Elsa Maitre, Edouard Cornet, Xavier Troussard
DISEASE OVERVIEW: Hairy cell leukemia (HCL) and HCL-like disorders, including HCL variant (HCL-V) and splenic diffuse red pulp lymphoma (SDRPL), are a very heterogeneous group of mature lymphoid B-cell disorders. They are characterized by the identification of hairy cells, a specific genetic profile, a different clinical course and the need for appropriate treatment. DIAGNOSIS: Diagnosis of HCL is based on morphological evidence of hairy cells, an HCL immunologic score of three or four based on the CD11C, CD103, CD123, and CD25 expression...
December 2019: American Journal of Hematology
https://read.qxmd.com/read/31293969/the-minimal-residual-disease-in-non-hodgkin-s-lymphomas-from-the-laboratory-to-the-clinical-practice
#28
REVIEW
Sara Galimberti, Elisa Genuardi, Francesco Mazziotta, Lorenzo Iovino, Fortunato Morabito, Susanna Grassi, Elena Ciabatti, Francesca Guerrini, Mario Petrini
Minimal residual disease (MRD) in non-Hodgkin's lymphomas (NHLs) still represents matter of interest and debate: indeed, the new available treatments offer higher rates of complete responses and MRD negativity than in the past, with a positive impact on the long-term survival. Furthermore, the introduction of more sensitive and accurate molecular techniques, such as digital PCR (ddPCR) and the next generation sequencing techniques (NGS), increased the possibility of identifying molecular targets to be followed after therapy (such as rearrangement of immunoglobulins, fusion genes, or mutations)...
2019: Frontiers in Oncology
https://read.qxmd.com/read/31563077/upfront-treatment-for-newly-diagnosed-transplant-ineligible-multiple-myeloma-patients-a-systematic-review-and-network-meta-analysis-of-14-533-patients-over-29-randomized-clinical-trials
#29
JOURNAL ARTICLE
Leo Sekine, Patrícia Klarmann Ziegelmann, Denise Manica, Carolina da Fonte Pithan, Monalisa Sosnoski, Vinicius Daudt Morais, Frederico Soares Falcetta, Mariana Rangel Ribeiro, Ana Paula Salazar, Rodrigo Antonini Ribeiro
Choice of treatment for newly diagnosed transplant-ineligible multiple myeloma poses a difficult task due to an ever-increasing plethora of different regimens. Attempting to clarify this subject, we performed a systematic review and Bayesian network meta-analysis of 29 randomized clinical trials, enrolling 14,533 patients, and comparing 25 different treatment regimens regarding overall survival(OS), progression-free survival(PFS), complete response(CR), overall response rate(ORR) and toxicity. Head-to-head comparisons for all regimens and ranking of best treatments are reported...
November 2019: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/31492632/2019-international-clinical-practice-guidelines-for-the-treatment-and-prophylaxis-of-venous-thromboembolism-in-patients-with-cancer
#30
JOURNAL ARTICLE
Dominique Farge, Corinne Frere, Jean M Connors, Cihan Ay, Alok A Khorana, Andres Munoz, Benjamin Brenner, Ajay Kakkar, Hanadi Rafii, Susan Solymoss, Dialina Brilhante, Manuel Monreal, Henri Bounameaux, Ingrid Pabinger, James Douketis
Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer. These patients are at a high risk of VTE recurrence and bleeding during anticoagulant therapy. The International Initiative on Thrombosis and Cancer is an independent academic working group aimed at establishing a global consensus for the treatment and prophylaxis of VTE in patients with cancer. The International Initiative on Thrombosis and Cancer last updated its evidence-based clinical practice guidelines in 2016 with a free, web-based mobile phone application, which was subsequently endorsed by the International Society on Thrombosis and Haemostasis...
October 2019: Lancet Oncology
https://read.qxmd.com/read/31527073/how-i-treat-waldenstr%C3%A3-m-macroglobulinemia
#31
REVIEW
Meletios A Dimopoulos, Efstathios Kastritis
Waldenström macroglobulinemia (WM) is an uncommon lymphoma characterized by the infiltration of the bone marrow by clonal lymphoplasmacytic cells that produce monoclonal immunoglobulin M (IgM). The disease may have an asymptomatic phase, or patients may present with symptoms and complications resulting from marrow or other tissue infiltration, or from physicochemical or immunological properties of the monoclonal IgM. Diagnosis of WM has been clearly defined, and genetic testing for somatic mutation of MYD88L265P is a useful tool for differential diagnosis from other conditions...
December 5, 2019: Blood
https://read.qxmd.com/read/31477227/managing-antiphospholipid-syndrome-in-pregnancy
#32
REVIEW
Karen Schreiber, Beverley J Hunt
Antiphospholipid syndrome (APS) is an autoimmune disease characterised by the presence of antiphospholipid antibodies (aPL). The antibodies currently included in the classification criteria include lupus anticoagulant (LA), anticardiolipin antibodies (aCL) and anti-^2-glycoprotein 1 antibodies (^2GPI). APS can present with a variety of clinical phenotypes, including thrombosis in the veins, arteries and microvasculature and obstetrical complications. Pregnancy complications in obstetric APS (OAPS) include unexplained recurrent early pregnancy loss, fetal death, or premature birth due to severe preeclampsia, eclampsia, intrauterine growth restriction or other consequences of placental insufficiency...
September 2019: Thrombosis Research
https://read.qxmd.com/read/31270855/diagnosis-and-management-of-follicular-lymphoma-a-comprehensive-review
#33
REVIEW
Reyad Dada
Follicular Lymphoma (FL) is an indolent lymphoma and may have various clinical courses. Worldwide, FL is the second most common non-Hodgkin lymphoma (NHL) type after diffuse large B-cell lymphoma. In this review article, the author is discussing relevant diagnostic tools, prognostic factors, and updated study results on the management of patients with newly diagnosed and relapsed/refractory FL. Controversies in the treatment, maintenance therapy, stem cell transplantation, and novel treatment approaches will be comprehensively discussed...
September 2019: European Journal of Haematology
https://read.qxmd.com/read/30288759/hypoalbuminemia-pathogenesis-and-clinical-significance
#34
REVIEW
Peter B Soeters, Robert R Wolfe, Alan Shenkin
Hypoalbuminemia is associated with inflammation. Despite being addressed repeatedly in the literature, there is still confusion regarding its pathogenesis and clinical significance. Inflammation increases capillary permeability and escape of serum albumin, leading to expansion of interstitial space and increasing the distribution volume of albumin. The half-life of albumin has been shown to shorten, decreasing total albumin mass. These 2 factors lead to hypoalbuminemia despite increased fractional synthesis rates in plasma...
February 2019: JPEN. Journal of Parenteral and Enteral Nutrition
https://read.qxmd.com/read/30719265/epigenetic-therapy-combinations-in-acute-myeloid-leukemia-what-are-the-options
#35
REVIEW
Jan Philipp Bewersdorf, Rory Shallis, Maximilian Stahl, Amer M Zeidan
Epigenetics refers to the regulation of gene expression mainly by changes in DNA methylation and modifications of histone proteins without altering the actual DNA sequence. While epigenetic modifications are essential for normal cell differentiation, several driver mutations in leukemic pathogenesis have been identified in genes that affect epigenetic processes, such as DNA methylation and histone acetylation. Several therapeutic options to target epigenetic alterations in acute myeloid leukemia (AML) have been successfully tested in preclinical studies and various drugs have already been approved for use in clinical practice...
2019: Therapeutic Advances in Hematology
https://read.qxmd.com/read/30740662/biology-and-therapy-of-primary-mediastinal-b-cell-lymphoma-current-status-and-future-directions
#36
REVIEW
Charlotte Lees, Colm Keane, Maher K Gandhi, Jay Gunawardana
Primary mediastinal B-cell lymphoma (PMBCL) is a distinct disease closely related to classical nodular sclerosing Hodgkin lymphoma. Conventional diagnostic paradigms utilising clinical, morphological and immunophenotypical features can be challenging due to overlapping features with other B-cell lymphomas. Reliable diagnostic and prognostic biomarkers that are applicable to the conventional diagnostic laboratory are largely lacking. Nuclear factor kappa B (NF-κB) and Janus kinase/signal transducers and activators of transcription (JAK-STAT) signalling pathways are characteristically dysregulated in PMBCL and implicated in several aspects of disease pathogenesis, and the latter pathway in host immune evasion...
April 2019: British Journal of Haematology
https://read.qxmd.com/read/30499630/how-i-investigate-eosinophilia
#37
REVIEW
Rebecca L Larsen, Natasha M Savage
Eosinophilia is typically secondary, that is, reactive, in nature and is associated with a wide variety of neoplastic and non-neoplastic disorders. Clonal eosinophilia is also seen in a wide variety of hematopoietic neoplasms, and sub-classification can be diagnostically challenging. A proper evaluation of persistent eosinophilia involves correlation of clinical history, laboratory data, cellular morphology, and ancillary testing. Knowledge of appropriate ancillary testing is necessary for a timely diagnosis...
April 2019: International Journal of Laboratory Hematology
https://read.qxmd.com/read/30478093/how-i-treat-cancer-associated-venous-thromboembolism
#38
JOURNAL ARTICLE
Noémie Kraaijpoel, Marc Carrier
Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a common complication of cancer and is associated with significant morbidity and mortality. Several cancer-related risk factors contribute to the development of VTE including cancer type and stage, chemotherapy, surgery, and patient-related factors such as advanced age and immobilization. Patients with cancer frequently undergo diagnostic imaging scans for cancer staging and treatment response evaluation, which is increasing the underlying risk of VTE detection...
January 24, 2019: Blood
https://read.qxmd.com/read/29214694/myelodysplastic-syndromes-2018-update-on-diagnosis-risk-stratification-and-management
#39
JOURNAL ARTICLE
Guillermo Montalban-Bravo, Guillermo Garcia-Manero
DISEASE OVERVIEW: The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males and in individuals with prior exposure to cytotoxic therapy. DIAGNOSIS: Diagnosis of MDS is based on morphological evidence of dysplasia upon visual examination of a bone marrow aspirate and biopsy. Information obtained from additional studies such as karyotype, flow cytometry or molecular genetics is usually complementary and may help refine diagnosis...
January 2018: American Journal of Hematology
https://read.qxmd.com/read/30328142/waldenstr%C3%A3-m-macroglobulinemia-2019-update-on-diagnosis-risk-stratification-and-management
#40
JOURNAL ARTICLE
Morie A Gertz
DISEASE OVERVIEW: Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity. DIAGNOSIS: Presence of IgM monoclonal protein associated with ≥10% clonal lymphoplasmacytic cells in bone marrow confirms the diagnosis. The L265P mutation in MYD88 is detectable in >90% of patients and is found in the majority of IgM monoclonal gammopathy of undetermined significance patients...
February 2019: American Journal of Hematology
label_collection
label_collection
3426
2
3
2018-11-11 19:30:20
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.